151 related articles for article (PubMed ID: 17448534)
21. Diagnostic and prognostic significance of gene expression profiling in lymphomas.
Leich E; Hartmann EM; Burek C; Ott G; Rosenwald A
APMIS; 2007 Oct; 115(10):1135-46. PubMed ID: 18042147
[TBL] [Abstract][Full Text] [Related]
22. Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
Li D; Deng J; He H; Bu Y; Peng F; Tang X; Wang B; Lei Y; Zhang H; Xie P
Ann Diagn Pathol; 2012 Oct; 16(5):335-43. PubMed ID: 22569408
[TBL] [Abstract][Full Text] [Related]
23. Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype.
Harris J; Ibrahim H; Amen F; Karadimitris A; Naresh KN; Macdonald DH
Hematol Oncol; 2012 Mar; 30(1):8-12. PubMed ID: 21638304
[TBL] [Abstract][Full Text] [Related]
24. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
25. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.
Zainuddin N; Berglund M; Wanders A; Ren ZP; Amini RM; Lindell M; Kanduri M; Roos G; Rosenquist R; Enblad G
Leuk Res; 2009 Jan; 33(1):60-6. PubMed ID: 18706692
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD68+ tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis.
Hasselblom S; Hansson U; Sigurdardottir M; Nilsson-Ehle H; Ridell B; Andersson PO
Pathol Int; 2008 Aug; 58(8):529-32. PubMed ID: 18705775
[TBL] [Abstract][Full Text] [Related]
27. Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Asrini R; Ham MF; Asmarinah A; Harahap AS; Hardjolukito ESR
Mol Clin Oncol; 2022 Feb; 16(2):42. PubMed ID: 35003740
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of diffuse large B-cell lymphoma supervised by CD21 expression.
Miyazaki K; Yamaguchi M; Suguro M; Choi W; Ji Y; Xiao L; Zhang W; Ogawa S; Katayama N; Shiku H; Kobayashi T
Br J Haematol; 2008 Aug; 142(4):562-70. PubMed ID: 18537973
[TBL] [Abstract][Full Text] [Related]
29. Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma.
Hashmi AA; Iftikhar SN; Nargus G; Ahmed O; Asghar IA; Shirazi UA; Afzal A; Irfan M; Ali J
Cureus; 2021 Feb; 13(2):e13120. PubMed ID: 33728138
[TBL] [Abstract][Full Text] [Related]
30. Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia.
Istiadi H; Sadhana U; Puspasari D; Miranti IP; Karlowee V; Listiana DE; Prasetyo A
Yonago Acta Med; 2021 May; 64(2):200-206. PubMed ID: 34025195
[TBL] [Abstract][Full Text] [Related]
31. Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression.
Yuan J; Gu K; He J; Sharma S
Hum Pathol; 2013 Apr; 44(4):606-11. PubMed ID: 23089492
[TBL] [Abstract][Full Text] [Related]
32. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell lymphoma showing an interfollicular pattern of proliferation: a study of the Osaka Lymphoma Study Group.
Yamauchi A; Ikeda J; Nakamichi I; Kohara M; Fukuhara S; Hino M; Kanakura Y; Ogawa H; Sugiyama H; Kanamaru A; Aozasa K;
Histopathology; 2008 May; 52(6):731-7. PubMed ID: 18397280
[TBL] [Abstract][Full Text] [Related]
34. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
van Galen JC; Muris JJ; Giroth CP; Vos W; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Histopathology; 2008 Apr; 52(5):578-84. PubMed ID: 18312353
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical subtyping of diffuse large B-cell lymphoma into germinal center B-cell and activated B-cell subtype, along with correlation of the subtypes with extranodal involvement, serum lactate dehydrogenase, and positron emission tomography scan-based response assessment to chemotherapy.
Tyagi A; Abrari A; Khurana A; Tyagi S
J Cancer Res Ther; 2022; 18(4):1129-1136. PubMed ID: 36149172
[TBL] [Abstract][Full Text] [Related]
36. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma.
Chuang SS; Ye H; Yang SF; Huang WT; Chen HK; Hsieh PP; Hwang WS; Chang KY; Lu CL; Du MQ
Histopathology; 2008 Oct; 53(4):432-40. PubMed ID: 18983608
[TBL] [Abstract][Full Text] [Related]
37. Expressions of glucose transporter Types 1 and 3 and hexokinase-II in diffuse large B-cell lymphoma and other B-cell non-Hodgkin's lymphomas.
Shim HK; Lee WW; Park SY; Kim H; So Y; Kim SE
Nucl Med Biol; 2009 Feb; 36(2):191-7. PubMed ID: 19217531
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.
Fang C; Zhu D; Dong H; Ji M; Wu J; Xu X; Cheng G; Wu C; Jiang J
Int J Clin Exp Med; 2015; 8(7):10705-13. PubMed ID: 26379862
[TBL] [Abstract][Full Text] [Related]
39. Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma.
Imai H; Shimada K; Shimada S; Abe M; Okamoto M; Kitamura K; Kinoshita T; Shiraishi T; Nakamura S
Pathol Int; 2009 Jul; 59(7):431-7. PubMed ID: 19563405
[TBL] [Abstract][Full Text] [Related]
40. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
